Concepts (90)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombophilia | 1 | 2019 | 8 | 0.620 |
Why?
|
| Hematologic Tests | 1 | 2019 | 13 | 0.620 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 49 | 0.600 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 29 | 0.600 |
Why?
|
| Pacemaker, Artificial | 3 | 2025 | 42 | 0.600 |
Why?
|
| Unnecessary Procedures | 1 | 2019 | 18 | 0.590 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 52 | 0.580 |
Why?
|
| Hospital Costs | 1 | 2019 | 51 | 0.580 |
Why?
|
| Education, Medical, Continuing | 1 | 2019 | 58 | 0.570 |
Why?
|
| Anticoagulants | 1 | 2019 | 143 | 0.560 |
Why?
|
| Inpatients | 1 | 2019 | 88 | 0.560 |
Why?
|
| Echocardiography | 1 | 2019 | 202 | 0.540 |
Why?
|
| Cardiomyopathies | 3 | 2023 | 70 | 0.520 |
Why?
|
| Torsades de Pointes | 1 | 2017 | 1 | 0.510 |
Why?
|
| Loperamide | 1 | 2017 | 2 | 0.510 |
Why?
|
| Self Medication | 1 | 2017 | 8 | 0.510 |
Why?
|
| Internship and Residency | 1 | 2019 | 330 | 0.450 |
Why?
|
| Tachycardia, Ventricular | 2 | 2025 | 26 | 0.420 |
Why?
|
| Clinical Alarms | 1 | 2025 | 5 | 0.230 |
Why?
|
| Electric Countershock | 1 | 2025 | 18 | 0.230 |
Why?
|
| Defibrillators, Implantable | 1 | 2025 | 44 | 0.220 |
Why?
|
| Ventricular Premature Complexes | 1 | 2023 | 20 | 0.200 |
Why?
|
| Atrial Fibrillation | 1 | 2025 | 411 | 0.160 |
Why?
|
| Humans | 10 | 2025 | 34562 | 0.160 |
Why?
|
| Diabetic Nephropathies | 1 | 2022 | 228 | 0.160 |
Why?
|
| Sarcoidosis | 1 | 2019 | 33 | 0.150 |
Why?
|
| Hemorrhage | 1 | 2019 | 109 | 0.150 |
Why?
|
| Cost Savings | 1 | 2019 | 39 | 0.150 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 542 | 0.140 |
Why?
|
| Recurrence | 1 | 2019 | 296 | 0.140 |
Why?
|
| Quality Indicators, Health Care | 1 | 2019 | 64 | 0.140 |
Why?
|
| Male | 7 | 2025 | 20740 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 197 | 0.140 |
Why?
|
| Feasibility Studies | 1 | 2019 | 323 | 0.140 |
Why?
|
| Health Care Costs | 1 | 2019 | 126 | 0.140 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 193 | 0.130 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 939 | 0.120 |
Why?
|
| Electrocardiography | 2 | 2019 | 657 | 0.120 |
Why?
|
| Retrospective Studies | 2 | 2025 | 3825 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 364 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2019 | 1910 | 0.110 |
Why?
|
| Adult | 2 | 2019 | 10030 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 755 | 0.110 |
Why?
|
| Heart Failure | 1 | 2022 | 780 | 0.110 |
Why?
|
| Middle Aged | 4 | 2025 | 12726 | 0.110 |
Why?
|
| Hypertension | 1 | 2022 | 1024 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 1209 | 0.100 |
Why?
|
| Female | 5 | 2025 | 21532 | 0.100 |
Why?
|
| Prospective Studies | 1 | 2019 | 2463 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 1523 | 0.100 |
Why?
|
| Heterocyclic Compounds | 1 | 2011 | 16 | 0.090 |
Why?
|
| Naltrexone | 1 | 2011 | 23 | 0.090 |
Why?
|
| Receptors, Opioid, mu | 1 | 2011 | 36 | 0.080 |
Why?
|
| Narcotic Antagonists | 1 | 2011 | 47 | 0.080 |
Why?
|
| Ventricular Function, Left | 2 | 2023 | 287 | 0.080 |
Why?
|
| Stroke Volume | 2 | 2023 | 440 | 0.070 |
Why?
|
| Time Factors | 2 | 2025 | 2353 | 0.070 |
Why?
|
| Aged | 3 | 2025 | 11022 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2025 | 3623 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2025 | 4157 | 0.060 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2025 | 73 | 0.050 |
Why?
|
| Phenethylamines | 1 | 2023 | 5 | 0.050 |
Why?
|
| Heart Rate | 1 | 2025 | 372 | 0.050 |
Why?
|
| Equipment Design | 1 | 2023 | 192 | 0.050 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2023 | 103 | 0.050 |
Why?
|
| Biphenyl Compounds | 1 | 2022 | 21 | 0.050 |
Why?
|
| Incidence | 1 | 2025 | 1290 | 0.040 |
Why?
|
| Tetrazoles | 1 | 2022 | 62 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2022 | 107 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2025 | 1508 | 0.040 |
Why?
|
| Twins, Monozygotic | 1 | 2019 | 13 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2022 | 379 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 318 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2022 | 901 | 0.030 |
Why?
|
| Risk Factors | 1 | 2025 | 4137 | 0.030 |
Why?
|
| Caco-2 Cells | 1 | 2011 | 7 | 0.020 |
Why?
|
| Morphine Dependence | 1 | 2011 | 2 | 0.020 |
Why?
|
| Membranes | 1 | 2011 | 12 | 0.020 |
Why?
|
| Drug Implants | 1 | 2011 | 11 | 0.020 |
Why?
|
| Cricetulus | 1 | 2011 | 21 | 0.020 |
Why?
|
| CHO Cells | 1 | 2011 | 29 | 0.020 |
Why?
|
| Cricetinae | 1 | 2011 | 52 | 0.020 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2011 | 35 | 0.020 |
Why?
|
| Narcotics | 1 | 2011 | 32 | 0.020 |
Why?
|
| Thalamus | 1 | 2011 | 39 | 0.020 |
Why?
|
| Morphine | 1 | 2011 | 54 | 0.020 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2011 | 76 | 0.020 |
Why?
|
| Rats | 1 | 2011 | 1946 | 0.020 |
Why?
|
| Mice | 1 | 2011 | 2720 | 0.010 |
Why?
|
| Animals | 1 | 2011 | 8579 | 0.010 |
Why?
|